Clinical and biological model for evaluation of the effectiveness of systemic therapy for breast cancer

V. F. Semiglazov, P. V. Krivorotko, G. A. Dashyan, T. Yu Semiglazova, A. V. Komyakhov, E. A. Busko, V. V. Semiglazov, A. S. Artemieva, V. V. Klimenko, A. G. Kudaibergenova, V. O. Bashlyk, A. V. Mishchenko, E. S. Trufanova, S. S. Ereshchenko, A. I. Tseluiko, A. M. Belyaev, P. I. Krzhivitsky

Research output

Abstract

Purpose: To create a unified system of accelerated clinical trials of new drugs and regimens for breast cancer (BC). Materials and methods: The study included 1214 patients with BC of different stages (cT1N1, cT2N1-2, cT2-3N0-2, cT2-3N0-1, cT4N0M0). According to trepan biopsy data and immunohistochemical examination (IHC) expression of ER, PR, HER2, and Ki67 was determined. The expression TUBBβIII, TOP2α, analyzes on the BRCA1/2 mutation was studied. The clinical response to neoadjuvant treatment was determined using the physical method, ultrasonography-elastography, mammography, contrast magnetic resonance imaging (MRI) and single-photon emission computer mammotography (SPECT-CT). Results: The correlation index of complete responses (cCR) and total pathomorphological responses (pCR) according to MRI was 0.80, according to ultrasound - 0.61, mammography - 0.60, palpation - 0.57. The low level of amplification of the TUBβIII mRNA gene with a high level of amplification of the TOP2-α gene is a predictor of the achievement of pCR. The inclusion of a neoadjuvant treatment of triply-negative BC carboplatin in addition to paclitaxel or eribulin increases the frequency of reaching pCR (ypT0/is(yp)N0) from 20.3% to 47%.

Original languageEnglish
Pages (from-to)289-297
Number of pages9
JournalVoprosy Onkologii
Volume64
Issue number3
Publication statusPublished - 1 Jan 2018

Fingerprint

Biological Models
Neoadjuvant Therapy
eribulin
Breast Neoplasms
Magnetic Resonance Imaging
Mammary Ultrasonography
Elasticity Imaging Techniques
Gene Amplification
Palpation
Carboplatin
Mammography
Paclitaxel
Photons
Ultrasonography
Therapeutics
Clinical Trials
Biopsy
Messenger RNA
Mutation
Pharmaceutical Preparations

Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Semiglazov, V. F., Krivorotko, P. V., Dashyan, G. A., Semiglazova, T. Y., Komyakhov, A. V., Busko, E. A., ... Krzhivitsky, P. I. (2018). Clinical and biological model for evaluation of the effectiveness of systemic therapy for breast cancer. Voprosy Onkologii, 64(3), 289-297.
Semiglazov, V. F. ; Krivorotko, P. V. ; Dashyan, G. A. ; Semiglazova, T. Yu ; Komyakhov, A. V. ; Busko, E. A. ; Semiglazov, V. V. ; Artemieva, A. S. ; Klimenko, V. V. ; Kudaibergenova, A. G. ; Bashlyk, V. O. ; Mishchenko, A. V. ; Trufanova, E. S. ; Ereshchenko, S. S. ; Tseluiko, A. I. ; Belyaev, A. M. ; Krzhivitsky, P. I. / Clinical and biological model for evaluation of the effectiveness of systemic therapy for breast cancer. In: Voprosy Onkologii. 2018 ; Vol. 64, No. 3. pp. 289-297.
@article{969392ccab2d40068a5f7c66e684f557,
title = "Clinical and biological model for evaluation of the effectiveness of systemic therapy for breast cancer",
abstract = "Purpose: To create a unified system of accelerated clinical trials of new drugs and regimens for breast cancer (BC). Materials and methods: The study included 1214 patients with BC of different stages (cT1N1, cT2N1-2, cT2-3N0-2, cT2-3N0-1, cT4N0M0). According to trepan biopsy data and immunohistochemical examination (IHC) expression of ER, PR, HER2, and Ki67 was determined. The expression TUBBβIII, TOP2α, analyzes on the BRCA1/2 mutation was studied. The clinical response to neoadjuvant treatment was determined using the physical method, ultrasonography-elastography, mammography, contrast magnetic resonance imaging (MRI) and single-photon emission computer mammotography (SPECT-CT). Results: The correlation index of complete responses (cCR) and total pathomorphological responses (pCR) according to MRI was 0.80, according to ultrasound - 0.61, mammography - 0.60, palpation - 0.57. The low level of amplification of the TUBβIII mRNA gene with a high level of amplification of the TOP2-α gene is a predictor of the achievement of pCR. The inclusion of a neoadjuvant treatment of triply-negative BC carboplatin in addition to paclitaxel or eribulin increases the frequency of reaching pCR (ypT0/is(yp)N0) from 20.3{\%} to 47{\%}.",
keywords = "Biological subtypes, Breast cancer, Radiological diagnostic methods, Systemic treatment",
author = "Semiglazov, {V. F.} and Krivorotko, {P. V.} and Dashyan, {G. A.} and Semiglazova, {T. Yu} and Komyakhov, {A. V.} and Busko, {E. A.} and Semiglazov, {V. V.} and Artemieva, {A. S.} and Klimenko, {V. V.} and Kudaibergenova, {A. G.} and Bashlyk, {V. O.} and Mishchenko, {A. V.} and Trufanova, {E. S.} and Ereshchenko, {S. S.} and Tseluiko, {A. I.} and Belyaev, {A. M.} and Krzhivitsky, {P. I.}",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "64",
pages = "289--297",
journal = "Voprosy Onkologii",
issn = "0507-3758",
publisher = "Медицина",
number = "3",

}

Semiglazov, VF, Krivorotko, PV, Dashyan, GA, Semiglazova, TY, Komyakhov, AV, Busko, EA, Semiglazov, VV, Artemieva, AS, Klimenko, VV, Kudaibergenova, AG, Bashlyk, VO, Mishchenko, AV, Trufanova, ES, Ereshchenko, SS, Tseluiko, AI, Belyaev, AM & Krzhivitsky, PI 2018, 'Clinical and biological model for evaluation of the effectiveness of systemic therapy for breast cancer', Voprosy Onkologii, vol. 64, no. 3, pp. 289-297.

Clinical and biological model for evaluation of the effectiveness of systemic therapy for breast cancer. / Semiglazov, V. F.; Krivorotko, P. V.; Dashyan, G. A.; Semiglazova, T. Yu; Komyakhov, A. V.; Busko, E. A.; Semiglazov, V. V.; Artemieva, A. S.; Klimenko, V. V.; Kudaibergenova, A. G.; Bashlyk, V. O.; Mishchenko, A. V.; Trufanova, E. S.; Ereshchenko, S. S.; Tseluiko, A. I.; Belyaev, A. M.; Krzhivitsky, P. I.

In: Voprosy Onkologii, Vol. 64, No. 3, 01.01.2018, p. 289-297.

Research output

TY - JOUR

T1 - Clinical and biological model for evaluation of the effectiveness of systemic therapy for breast cancer

AU - Semiglazov, V. F.

AU - Krivorotko, P. V.

AU - Dashyan, G. A.

AU - Semiglazova, T. Yu

AU - Komyakhov, A. V.

AU - Busko, E. A.

AU - Semiglazov, V. V.

AU - Artemieva, A. S.

AU - Klimenko, V. V.

AU - Kudaibergenova, A. G.

AU - Bashlyk, V. O.

AU - Mishchenko, A. V.

AU - Trufanova, E. S.

AU - Ereshchenko, S. S.

AU - Tseluiko, A. I.

AU - Belyaev, A. M.

AU - Krzhivitsky, P. I.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: To create a unified system of accelerated clinical trials of new drugs and regimens for breast cancer (BC). Materials and methods: The study included 1214 patients with BC of different stages (cT1N1, cT2N1-2, cT2-3N0-2, cT2-3N0-1, cT4N0M0). According to trepan biopsy data and immunohistochemical examination (IHC) expression of ER, PR, HER2, and Ki67 was determined. The expression TUBBβIII, TOP2α, analyzes on the BRCA1/2 mutation was studied. The clinical response to neoadjuvant treatment was determined using the physical method, ultrasonography-elastography, mammography, contrast magnetic resonance imaging (MRI) and single-photon emission computer mammotography (SPECT-CT). Results: The correlation index of complete responses (cCR) and total pathomorphological responses (pCR) according to MRI was 0.80, according to ultrasound - 0.61, mammography - 0.60, palpation - 0.57. The low level of amplification of the TUBβIII mRNA gene with a high level of amplification of the TOP2-α gene is a predictor of the achievement of pCR. The inclusion of a neoadjuvant treatment of triply-negative BC carboplatin in addition to paclitaxel or eribulin increases the frequency of reaching pCR (ypT0/is(yp)N0) from 20.3% to 47%.

AB - Purpose: To create a unified system of accelerated clinical trials of new drugs and regimens for breast cancer (BC). Materials and methods: The study included 1214 patients with BC of different stages (cT1N1, cT2N1-2, cT2-3N0-2, cT2-3N0-1, cT4N0M0). According to trepan biopsy data and immunohistochemical examination (IHC) expression of ER, PR, HER2, and Ki67 was determined. The expression TUBBβIII, TOP2α, analyzes on the BRCA1/2 mutation was studied. The clinical response to neoadjuvant treatment was determined using the physical method, ultrasonography-elastography, mammography, contrast magnetic resonance imaging (MRI) and single-photon emission computer mammotography (SPECT-CT). Results: The correlation index of complete responses (cCR) and total pathomorphological responses (pCR) according to MRI was 0.80, according to ultrasound - 0.61, mammography - 0.60, palpation - 0.57. The low level of amplification of the TUBβIII mRNA gene with a high level of amplification of the TOP2-α gene is a predictor of the achievement of pCR. The inclusion of a neoadjuvant treatment of triply-negative BC carboplatin in addition to paclitaxel or eribulin increases the frequency of reaching pCR (ypT0/is(yp)N0) from 20.3% to 47%.

KW - Biological subtypes

KW - Breast cancer

KW - Radiological diagnostic methods

KW - Systemic treatment

UR - http://www.scopus.com/inward/record.url?scp=85052728426&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85052728426

VL - 64

SP - 289

EP - 297

JO - Voprosy Onkologii

JF - Voprosy Onkologii

SN - 0507-3758

IS - 3

ER -

Semiglazov VF, Krivorotko PV, Dashyan GA, Semiglazova TY, Komyakhov AV, Busko EA et al. Clinical and biological model for evaluation of the effectiveness of systemic therapy for breast cancer. Voprosy Onkologii. 2018 Jan 1;64(3):289-297.